Third-party testing certificates of analysis (COAs), ideally with HPLC and mass spectrometry data, are the main quality-assurance tool available
Ozempic and the Risk of nAMD A recent article in JAMA Ophthamology (June 2025) suggests that vascular changes triggered by GLP-1 activity may trigger or worsen nAMD in some patients, especially those who are older, diabetic, or already at risk for macular degeneration
While thrombosis is a known post-splenectomy consequence, our findings indicate a significant increase in platelet activation, hypercoagulation, serum ferritin as well as the up-regulation of platelet proteins in non-splenectomized patients, suggesting a closer monitoring of thrombosis in this group of patients is also needed
Glucagon is a hormone that increases blood sugar levels when necessary
Symptoms alone cannot prove that a GLP-1 medication caused gastroparesis
(Lond) 2021;61:169171